Sign up to receive information about primary immunodeficiency and XEMBIFY.

Sign up today
Sign up today
RESOURCES

Xembify ConnexionsTM offers support tools and resources to help you manage PI

Rikki’s experience as an IG Nurse Educator (IgNE)

Rikki, a Senior IG Nurse Educator with 11+ years of experience, shares her thoughts on PI and XEMBIFY.

Watch now
Watch now

Laura’s experience as an IG Nurse Educator (IgNE)

Laura, a Senior Clinical Nurse Educator with 30+ years of experience, shares her thoughts on PI and XEMBIFY.

Watch now
Watch now

XEMBIFY self-administration video

Experience the freedom and flexibility of administering your own infusions with a routine that is convenient for you.1

Watch now
Watch now

Register today for a XEMBIFY Patient Speaker Program

Learn more about PI, IG therapy, and XEMBIFY from a trained nurse, who will share information and insights for patients, caregivers, and families.

Register

IG Therapy Discussion Guide

Download this guide to help you learn more about IG therapy and prepare for your conversation with your healthcare team.

English Español
English Español

XEMBIFY Patient Brochure

Use this brochure to help you better understand PI and your XEMBIFY treatment. Download this brochure below or call Xembify ConnexionsTM at
1-844-MYXEMBIFY (1-844-699-3624) 
Monday through Friday, 8 AM to 8 PM ET to request a copy of this brochure.

English Español
English Español
Patient starter kit

Patient Starter Kit for XEMBIFY

The XEMBIFY Patient Starter Kit has educational resources designed for patients and caregivers. It is available for patients who are on XEMBIFY or who are preparing to start XEMBIFY. A kit can be requested by calling Xembify Connexions™ at 1-844-MYXEMBIFY (1-844-699-3624) Monday through Friday, 8 AM to 8 PM ET.

To learn more about the starter kit, patients or healthcare providers can visit the Xembify Connexions website or call 1-844-MYXEMBIFY (1-844-699-3624).

Order starter kit

The XEMBIFY Patient Starter Kit includes:

Quick reference infusion guide

Quick Reference Infusion Guide

Follow the steps, illustrated on this
easy-to-read mat, to prepare and administer your infusions. Its water-resistant surface can be cleaned easily for repeated use.

Infusion log book

Infusion Log Book

Track your infusions and how they feel, and remember to share your Infusion Log Book with your healthcare provider.

Buzzy mini personal device

Buzzy® Mini Personal

The Buzzy® Mini Personal device uses a patented combination of cold and vibration to reduce the pain of injections.

Children's therapy journal

Resources for children

Resources are also available for children who start therapy with XEMBIFY. These materials include an educational book (Our Immune System, from the Immune Deficiency Foundation) and a therapy journal with crayons and stickers to help children be more involved in their care and track their infusions.


These resources are also included in the XEMBIFY Patient Starter Kit, which is available to new patients through their specialty pharmacy or by calling Xembify Connexions.


To receive a new journal, call Xembify Connexions:
1-844-MYXEMBIFY (1-844-699-3624) Monday through Friday, 8 am to 8 pm ET.

Order here

Connecting you to helpful support organizations

Many organizations are dedicated to helping people manage PI and learn more about the condition. These websites are provided as a resource only and do not constitute an endorsement by Grifols of any particular content. Grifols does not review or control the content of non-Grifols websites.

The Immune Deficiency Foundation (IDF) Patient and physician resource for the research and education of primary immune deficiency diseases
The Jeffrey Modell Foundation (JMF) Global resource center for primary immunodeficiency that provides patient and physician materials, including a patient message board, a physician research library, and CME course regarding research and education about primary immunodeficiency
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) An international organization dedicated to advancing PI clinical care through medical education and global collaboration
The National Institute of Allergy and Infectious Diseases (NIAID) Part of the National Institutes of Health, the NIAID leads research to understand, treat, and prevent infectious, immunologic, and allergic diseases

To find out about more organizations that can offer support, please contact Xembify Connexions at 1-844-MYXEMBIFY (1-844-699-3624) Monday through Friday, 8 am to 8 pm ET

Want to receive information and support from Xembify Connexions™?

Sign up

Terms to Know

CME, continuing medical education; IG, immune globulin; PI, primary immunodeficiency disease.

What is XEMBIFY®?

XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

 

IMPORTANT SAFETY INFORMATION

 

WARNING: THROMBOSIS

  • Thrombosis (formation of blood clots within blood vessels) may occur with immune globulin products, including XEMBIFY. Before you take XEMBIFY, talk to your doctor if you:
    • Are older
    • Are sedentary (need to lie down or sit down) for long periods of time
    • Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
    • Have a permanent intravenous (IV) catheter
    • Have hyperviscosity of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
    • Have cardiovascular (heart) problems or previous history of stroke
  • Thrombosis may occur even if you don’t have any risk factors
  • If you are at risk of thrombosis, your doctor may prescribe XEMBIFY at the minimum dose and infusion rate. Make sure you drink plenty of fluid before taking XEMBIFY. Make sure your doctor is checking you regularly for signs and symptoms of thrombosis and is checking your blood viscosity if you are at risk of hyperviscosity

Who should not use XEMBIFY?

  • XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product

What are possible serious side effects of XEMBIFY?

  • Aseptic meningitis syndrome (AMS). Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache syndrome, which may occur with human immune globulin treatment, including XEMBIFY. If you are showing signs and symptoms of AMS, your doctor may conduct a thorough neurological evaluation including spinal tap (sampling fluid which surrounds the spinal cord) to rule out other causes of meningitis. Stopping human immune globulin treatment has resulted in the end of signs and symptoms within several days. Treatment may include analgesics (pain medicines) and/or a special procedure known as a “blood patch” to stop headache
  • Hypersensitivity. Severe allergic reactions may occur with immune globulin products, including XEMBIFY. If you have a severe allergic reaction, stop the infusion immediately and get medical attention. XEMBIFY contains IgA. If you have known antibodies to IgA, you may have a greater risk of developing potentially severe allergic reactions
  • Kidney problems or failure. Kidney problems or failure may occur with use of human immune globulin products, especially those containing sucrose (sugar). XEMBIFY does not contain sucrose. If you have kidney disease or diabetes with kidney involvement, your doctor should perform a blood test to assess your hydration level and kidney function before beginning immune globulin treatment and at appropriate intervals thereafter. If your doctor determines that kidney function is worsening, they may discontinue treatment
  • Hemolysis. Your doctor should monitor you for symptoms of hemolysis (destruction of red blood cells causing anemia, or low red blood cell count). If your doctor suspects hemolysis, they should perform additional tests to confirm
  • Transfusion-related acute lung injury (TRALI). TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. If your doctor suspects TRALI, they will monitor you for any other lung issues. TRALI may be managed with oxygen therapy
  • Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY
  • Interference with lab tests. Because XEMBIFY contains a variety of antibodies, blood tests to determine antibody levels may be falsely elevated. Be sure to tell your doctor or lab technician that you are using XEMBIFY

What are other possible side effects of XEMBIFY?

  • In clinical studies of XEMBIFY, some patients experienced local side effects (at the injection site) including pain, redness, puffiness, bruising, nodules, itching, firmness, scabbing and swelling at the site on the skin where the injection occurred. Some patients experienced non-injection-site side effects including cough and diarrhea
  • Use of XEMBIFY may interfere with the immune response to virus vaccines, such as vaccines for measles, mumps, rubella and varicella. Tell your doctor you are taking XEMBIFY before getting vaccinations

Please see accompanying full Prescribing Information for XEMBIFY.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Reference

  1. XEMBIFY Prescribing Information, Grifols. July 2024.